Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Celgene, VentiRx collaborate on TLR8 agonist
November 2012
SHARING OPTIONS:

SEATTLE—An exclusive, worldwide collaboration was announced early this month between privately held VentiRx Pharmaceuticals Inc. and Celgene Corp. for the development of VTX-2337, a highly potent, selective TLR8 agonist for treating cancer. Per the terms of the agreement, Celgene will pay $35 million up front for the funding of additional research and development of the compound through established clinical endpoints. In addition, Celgene will retain an exclusive option to acquire VentiRx, and during the option period, VentiRx will be eligible for additional funding as well as a potential equity investment by Celgene.

"We are excited to have the support of Celgene to advance our development efforts and optimize the potential of VTX-2337 as a novel immunotherapy that augments current treatment regimens," Dr. Robert Hershberg, CEO of VentiRx, said in a statement.






 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.